Locally Advanced Prostate Cancer: Optimal Therapy in Older Patients

被引:2
作者
Froehner, Michael [1 ]
Wirth, Manfred P. [1 ]
机构
[1] Tech Univ Dresden, Dept Urol, Univ Hosp Carl Gustav Carus, D-01304 Dresden, Germany
关键词
ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; FOLLOW-UP; BIOCHEMICAL RECURRENCE; CARDIOVASCULAR DEATH; FUNCTIONAL OUTCOMES; RADIATION-THERAPY; ONCOLOGY-GROUP; MEN; ASSOCIATION;
D O I
10.1007/s40266-013-0123-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
There is no standard treatment for locally advanced prostate cancer. Even the definition is still unclear. Locally advanced disease may refer to over-staged well-curable tumors as well as to advanced and probably incurable cancers. Similar uncertainties are present regarding the definition of 'old' in this context. Conservatively treated locally advanced prostate cancer is associated with poor survival outcome. With the increasing life expectancy, in the absence of curative treatment, even patients in their ninth decade of life may later suffer from symptoms of aggressive prostate cancer and are at a high risk of death from prostate cancer that might be prevented at least in part by early intervention. On the other hand, functional results after prostate cancer treatment are worse in elderly patients. In this article we discuss aspects of the management of locally advanced prostate cancer in the elderly with special focus on the recommendation of current clinical guidelines.
引用
收藏
页码:959 / 967
页数:9
相关论文
共 50 条
  • [21] Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients
    Ma, Cheng
    Cui, Di
    Han, Bangmin
    Ding, Mao
    Zhang, Jiahao
    Liu, Shiyun
    Gao, Yingli
    Xia, Shujie
    CANCER INVESTIGATION, 2023, 41 (04) : 345 - 353
  • [22] Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer
    Manfred P. Wirth
    Michael Froehner
    Drugs & Aging, 2003, 20 : 115 - 124
  • [23] Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities
    Sridharan, S.
    Dal Pra, A.
    Catton, C.
    Bristow, R. G.
    Warde, P.
    CLINICAL ONCOLOGY, 2013, 25 (08) : 499 - 505
  • [24] Pharmacotherapeutic Management of Locally Advanced Prostate Cancer Current Status
    Martin, Jarad M.
    Supiot, Stephane
    Berthold, Dominik R.
    DRUGS, 2011, 71 (08) : 1019 - 1041
  • [25] Locally advanced prostate cancer
    Klein E.A.
    Kupelian P.A.
    Dreicer R.
    Peereboom D.
    Zippe C.
    Current Treatment Options in Oncology, 2001, 2 (5) : 403 - 411
  • [26] Radical prostatectomy in locally advanced prostate cancer
    Mandel, P.
    Tilki, D.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1394 - 1401
  • [27] Combined External Radiotherapy and Hormone Therapy in Patients with Locally Advanced Prostate Cancer: Predictive Factors of Genitourinary Toxicity
    Ferrandis, C.
    March, J. A.
    Martinez, J. M.
    Hernandez, J.
    Diez, N.
    Morillo, V.
    Garcia, F.
    Chuan, P.
    ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (03): : 146 - 151
  • [28] Young man with locally advanced prostate cancer
    Soloway M.
    Current Urology Reports, 2007, 8 (3) : 179 - 180
  • [29] Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer
    Hatoum, Hind T.
    Crawford, E. David
    Nielsen, Sandy Kildegaard
    Lin, Swu-Jane
    Marshall, Dennis C.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (02) : 261 - 270
  • [30] Treatment strategies for locally advanced prostate cancer
    Zhang Kai
    Zhang Xianghua
    CHINESE MEDICAL JOURNAL, 2014, 127 (05) : 957 - 960